WO2002049636A1 - An antidiabetic composition of amino acids - Google Patents

An antidiabetic composition of amino acids Download PDF

Info

Publication number
WO2002049636A1
WO2002049636A1 PCT/IN2000/000128 IN0000128W WO0249636A1 WO 2002049636 A1 WO2002049636 A1 WO 2002049636A1 IN 0000128 W IN0000128 W IN 0000128W WO 0249636 A1 WO0249636 A1 WO 0249636A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glycine
lysine
leucine
glutamic acid
Prior art date
Application number
PCT/IN2000/000128
Other languages
French (fr)
Inventor
Rajagopal Thiruvengadam
Malladi Surya Prakasa Sastry
Original Assignee
Rajagopal Thiruvengadam
Malladi Surya Prakasa Sastry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rajagopal Thiruvengadam, Malladi Surya Prakasa Sastry filed Critical Rajagopal Thiruvengadam
Priority to AU2001235976A priority Critical patent/AU2001235976A1/en
Priority to PCT/IN2000/000128 priority patent/WO2002049636A1/en
Publication of WO2002049636A1 publication Critical patent/WO2002049636A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • This invention relates to a novel composition consisting of bio-active and bio-acceptable amino acids for treatment and control of various forms of diabetes.
  • Diabetes Mellitus is an insidious disease, which has no cure at present and is considered to be a major global health problem. About 160 million people all over the world are currently estimated to be suffering from diabetes which according to WHO predictions is likely to cross the 300 million mark by the end of 2025. Incidence of diabetes has increased by 40% among the people in the age group of 40 and by 70% for people in the age group of 30 during 1990-1998. In India alone over 20 million diabetes patients need treatment. Diabetes is estimated to affect a significantly higher percentage of the population in India when compared with other countries. It is noticed that the Indian racial groups settled in other countries also show a higher rate of incidence when compared to other nationalities. These facts clearly indicated that Indians are more prone to diabetes.
  • IDM Insulin Dependant Diabetes Mellitus
  • NIDDM Non Insulin Dependant Diabetes Mellitus
  • Non insulin dependent diabetes can be controlled by proper and regulated diet and exercise. Blood sugar levels may thus be controlled and medication is avoided at least in the early stages of detection and in borderline cases. Howeyer, chronic cases require treatment both insulin and other anti-diabetic drugs. Incidence of this type of diabetes is also found to be on the increase and various anti-diabetic drugs and formulations are available in the market. These drugs act by stimulating insulin secretion, improving absorption of glucose and by increasing insulin sensitivity. In non-insulin dependent diabetes, insulin production may be normal but impaired glucose absorption and consequent increase in blood sugar level may be due to insulin resistance.
  • Major problems facing chronic diabetic patients are diabetic retinopathy, nephropathy, diabetic neuropathy, non- healing diabetic ulcers, neuritis, cataract retinopathy and heart ailments.
  • Proteins are known to stimulate insulin secretion and they do play an important role in the absorption and utilization of dietary carbohydrates. While there have been suggestions on the utility of amino acids for the control of blood sugar in hyperglycemic patients based on animal experiments there has been no systematic evaluation of their utility. For example, it has been reported that cataractogenis could be prevented by preventing glycation of lens proteins mediated by chronic diabetes. This, in turn, has lead to the suggestion lysine or a mixture of amino acids could be useful in the treatment of diabetes. However, it is reported that lowering of blood sugar is not immediate and sustained which lead to the hypothesis that the mechanism may be mostly through the scavenging of glucose by the amino acids administered (Sulochana et. al. Exp.
  • the tripeptide containing glycine, glutamic acid and cysteine residues has been studied with respect to its effect on diabetic animals and patients. It has been surmised that diabetes condition lowers the glutathione content in the liver and reduces the activity of Super oxide dismutase, an enzyme responsible for the elimination of active oxygen radicals, administration of glutathione to diabetic rats led to the recovery of liver glutathione concentration due to increased Super oxide dismutase activity. The impairment of glutathione metabolism weakens the defence mechanism against oxidative stress that the cells experience during the absorption phase of glucose. It has been reported that presence of diabetic complications correlated negatively with the concentration of reduce glutathione. Experimental work with animals has shown the protective effect of glutathione on beta cell toxicity in tiials aimed at reducing the beta cell damage in insulin dependent diabetes.
  • the object of the present invention is to address the basic drawbacks associated with the current management of diabetes, particularly, Non- insulin Dependent Diabetes Mellitus by developing an anti-diabetic preparation which combines many of the desirable features required for an ideal Anti-Diabetic Drug.
  • the essence of the present invention is related to the development of a novel concept for a novel and innovative method of treatment of acute and chronic diabetes and their attendant long-term complications, which affect the various tissues and organs in the human body.
  • the new approach is to utilize the most desirable combination of amino acids, based on their effect on insulin secretion, glucose absorption, insulin resistance, oxidative stress, diabetic cataractogenesis and retinopathy, and vascular complications.
  • the present invention resides in the remarkable finding that a composition of amino acids essentially containing lysine, glycine, leucine, glutamic acid an cysteine which may contain other biologically active and biologically acceptable amino acids has powerful anti diabetic properties.
  • Such compositions are found to exhibit blood sugar reducing properties and also inhibit insulin resistance.
  • Several long-term secondary complications of diabetes such as cataractogenesis, retinopathy, diabetic neuropathy and heart diseases are minimized on treatment with compositions of this invention.
  • a unit dosage of the composition of this invention may have the following composition
  • any known biologically acceptable amino acids may also be added to the composition.
  • composition of amino acids formulated, according to this invention were tested in Streptozotocin induced diabetic rats for its antihyperglycemic activity, in accordance with the defined protocol, with the positive (Phenformin) control and solvent control comparisons.
  • Albino rats of wistar strain of either sex weighing between the narrow range of weight of 150 to 200 gms were selected and were provided with water and standard commercial rat feed ad libitum. Animals were housed at temperature of 18 to 25 degrees C. Diabetes were induced in the rats by the administration of Streptozotocin at a single dose 50mg kg, intraperitonially to overnight fasted animals. Blood glucose levels were estimated by obtaining drop of blood from the tip of the rats toil and placing on a strip of lifescan Inc., USA and the values were measured using the glucometer. Blood glucose is estimated at intervals of 48 and 72 hours after Streptozotocin administration, to the overnight fasted animals which was considered as zero blood glucose value.
  • composition of the present invention contains nutritional principles, safety is guaranteed and toxic effects are bound to be minimum.
  • composition can be administered in a solid dosage form such as plain and coated tablets/hard gelatine capsules/soft gelatine capsules/powder in sachet/liquid dosage form like solution suspension and parental preparations.
  • Different dosage forms are prepared using the conventional excipients and the composition of the excipients may change depending upon the dosage form formulated.
  • Tablets or capsules are formulated by using suitable excipients like microcrystalline cellulose, potato starch, methyl cellulose, hydroxy propyl cellulose, dicalcium phosphate, poly ethylene glycol, hydroxy propyl methyl cellulose, talc, magnesium stearate etc. are used and the process for tabletting normally, not necessarily the same steps.
  • the capsules are formulated in two ways. They are
  • composition with or without the excipients can be used as a powder in a suitable packing like sachet etc..
  • composition can be formulated into a liquid using pharmaceutical vehicles like sorbitol, water, sugar syrup, propylene glycol, glycerine in addition to flavours, buffers, antioxidants and preservatives.
  • pharmaceutical vehicles like sorbitol, water, sugar syrup, propylene glycol, glycerine in addition to flavours, buffers, antioxidants and preservatives.
  • composition and process for extrusion and spheronisation technique is as follows.
  • the above ingredients are sieved through 40# and mixed in a suitable mixer for 30 mnts. And water is added slowly to obtain a soft mass. This is passed through an extruder and then spheronised. The spheronised granules are dried at 45 deg C for about 3 hours or till moisture content is less than
  • These two granules can also be taken as single granules, by taking all the materials together.
  • the blood glucose levels of the test group were 45% lower than that of the control group and 29% lower than that of positive control group.
  • the amino acid mixture could contain the raise in blood glucose level, in test group from the initial level, where as solvent treated control group continued to show significantly increasing blood glucose levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Present invention provides a selected composition of L-Lysine Hydrochloride, L-Leucine, L-Glycine, L-Cysteine hydrochloride and L-Glutamic acid, with very effective and safe antidiabetic properties and which in addition to reducing blood glucose levels in diabetes, has the potential to alleviate the secondary complications of the diabetes. The invention describes the composition of the above amino acids, process for the preparation of different formulations, including the preferred ranges and their use as anti diabetic agents.

Description

AN ANTIDIABETIC COMPOSITION OF AMINO ACIDS
Technical Field
This invention relates to a novel composition consisting of bio-active and bio-acceptable amino acids for treatment and control of various forms of diabetes.
Diabetes Mellitus is an insidious disease, which has no cure at present and is considered to be a major global health problem. About 160 million people all over the world are currently estimated to be suffering from diabetes which according to WHO predictions is likely to cross the 300 million mark by the end of 2025. Incidence of diabetes has increased by 40% among the people in the age group of 40 and by 70% for people in the age group of 30 during 1990-1998. In India alone over 20 million diabetes patients need treatment. Diabetes is estimated to affect a significantly higher percentage of the population in India when compared with other countries. It is noticed that the Indian racial groups settled in other countries also show a higher rate of incidence when compared to other nationalities. These facts clearly indicated that Indians are more prone to diabetes.
There are two major types of diabetes (1) Insulin Dependant Diabetes Mellitus (IDDM) and (2) Non Insulin Dependant Diabetes Mellitus (NIDDM). It is shown that incidence of insulin dependent diabetes is particularly high in Indian children below the age of 15 when compared to statistics from other countries. Insulin dependent diabetes is shown to have a strong genetic aetiology. Conventional treatment for this type of diabetes is administration of insulin extraneously in a rigorous and disciplined manner.
Non insulin dependent diabetes can be controlled by proper and regulated diet and exercise. Blood sugar levels may thus be controlled and medication is avoided at least in the early stages of detection and in borderline cases. Howeyer, chronic cases require treatment both insulin and other anti-diabetic drugs. Incidence of this type of diabetes is also found to be on the increase and various anti-diabetic drugs and formulations are available in the market. These drugs act by stimulating insulin secretion, improving absorption of glucose and by increasing insulin sensitivity. In non-insulin dependent diabetes, insulin production may be normal but impaired glucose absorption and consequent increase in blood sugar level may be due to insulin resistance. Major problems facing chronic diabetic patients are diabetic retinopathy, nephropathy, diabetic neuropathy, non- healing diabetic ulcers, neuritis, cataract retinopathy and heart ailments.
Proteins are known to stimulate insulin secretion and they do play an important role in the absorption and utilization of dietary carbohydrates. While there have been suggestions on the utility of amino acids for the control of blood sugar in hyperglycemic patients based on animal experiments there has been no systematic evaluation of their utility. For example, it has been reported that cataractogenis could be prevented by preventing glycation of lens proteins mediated by chronic diabetes. This, in turn, has lead to the suggestion lysine or a mixture of amino acids could be useful in the treatment of diabetes. However, it is reported that lowering of blood sugar is not immediate and sustained which lead to the hypothesis that the mechanism may be mostly through the scavenging of glucose by the amino acids administered (Sulochana et. al. Exp. Eye Research (1998) 67-, 597). Similarly while it is reported that amino acids can stimulate insulin release (Fajans et. al.), the pancreatic beta cells do not respond equally well to all amino acids. It was not clear as to what extent, the different capacities of individual amino acids to stimulate insulin release are related to differences in their metabolism (Hellmann et al., Biochem J (1971) 123, 513). For example, studies on rabbit and rat pancreas have indicated that leucine is able to elicit insulin release in a glucose free medium. Lysine has also been reported to ameliorate cataractogenesis in rats (Sulochana et al. Insight Vol. XV(3) 1997.
In addition to the free individual amino acids, such as leucine and lysine, glutathione, the tripeptide containing glycine, glutamic acid and cysteine residues has been studied with respect to its effect on diabetic animals and patients. It has been surmised that diabetes condition lowers the glutathione content in the liver and reduces the activity of Super oxide dismutase, an enzyme responsible for the elimination of active oxygen radicals, administration of glutathione to diabetic rats led to the recovery of liver glutathione concentration due to increased Super oxide dismutase activity. The impairment of glutathione metabolism weakens the defence mechanism against oxidative stress that the cells experience during the absorption phase of glucose. It has been reported that presence of diabetic complications correlated negatively with the concentration of reduce glutathione. Experimental work with animals has shown the protective effect of glutathione on beta cell toxicity in tiials aimed at reducing the beta cell damage in insulin dependent diabetes.
Earlier experimental data has suggested that diabetes bring about considerable oxidative stress which leads to organic damage in the long run. There is also evidence that glutathione, the master physiological anti-oxidant confers protection against the degenerative changes resulting from oxidative stress.
Administration of glutathione orally, however, may not be the right answer for solving the problems associated with control of diabetes, mediated through the use of use of glutathione, since there are doubts that administration of oral glutathione may not provide the blood levels required for pharmacological activity.
In summary, therefore, it is obvious that present day knowledge on the potential utility of amino acids for the control of hyperglycemia suffer from lack of information and evidence on the appropriate composition of amino acids required to meet the challenges of developing a product which has the ability to control blood sugar levels, reduce to the extent possible the long- term complications of chronic diabetes, tackle the problems of Insulin resistance and provide a physiologically acceptable preparation with little or no side effects. Disclosure of fhe invention
The object of the present invention is to address the basic drawbacks associated with the current management of diabetes, particularly, Non- insulin Dependent Diabetes Mellitus by developing an anti-diabetic preparation which combines many of the desirable features required for an ideal Anti-Diabetic Drug. The essence of the present invention is related to the development of a novel concept for a novel and innovative method of treatment of acute and chronic diabetes and their attendant long-term complications, which affect the various tissues and organs in the human body. The new approach is to utilize the most desirable combination of amino acids, based on their effect on insulin secretion, glucose absorption, insulin resistance, oxidative stress, diabetic cataractogenesis and retinopathy, and vascular complications.
Surprisingly, it has now been found that a composition of amino acids essentially containing lysine, leucine, cysteine, glycine and glutamic acid, the last three being the building blocks for the anti-oxidant glutathione exhibit excellent antidiabetes properties. The influence of glutathione as an effective anti-oxidant for reducing the oxidative stress in tissues and cells is well documented. There is also evidence that diabetes induces increased oxidative stress in cells and tissues, which may fiirther aggravate problems of glucose absorption. Decreased levels of glutathione and increase in the levels of glutathione oxidation products are noticed in diabetic patients. It is observed that glutathione is minimally absorbed and has low bioavailability. We have noticed that administration of component amino acids for the biosynthesis of glutathone namely glycine, glutamic acid and cysteine lead to increase in bioavailability of glutathione in vivo.
The present invention resides in the remarkable finding that a composition of amino acids essentially containing lysine, glycine, leucine, glutamic acid an cysteine which may contain other biologically active and biologically acceptable amino acids has powerful anti diabetic properties. Such compositions are found to exhibit blood sugar reducing properties and also inhibit insulin resistance. Several long-term secondary complications of diabetes such as cataractogenesis, retinopathy, diabetic neuropathy and heart diseases are minimized on treatment with compositions of this invention.
A unit dosage of the composition of this invention may have the following composition;
L- Lysine hydrochloride -125.00 to 1000 mg
L- Leucine - 25.85 to 206.80 mg
L- Cysteine hydrochloride - 16.58 to 132.64 mg
L- Glycine - 10.275 to 82.20 mg
L- Glutamic acid - 20.01 to 160.08 mg
In addition to the above referenced amino acids, any known biologically acceptable amino acids may also be added to the composition.
The composition of amino acids formulated, according to this invention, were tested in Streptozotocin induced diabetic rats for its antihyperglycemic activity, in accordance with the defined protocol, with the positive (Phenformin) control and solvent control comparisons.
Albino rats of wistar strain of either sex weighing between the narrow range of weight of 150 to 200 gms were selected and were provided with water and standard commercial rat feed ad libitum. Animals were housed at temperature of 18 to 25 degrees C. Diabetes were induced in the rats by the administration of Streptozotocin at a single dose 50mg kg, intraperitonially to overnight fasted animals. Blood glucose levels were estimated by obtaining drop of blood from the tip of the rats toil and placing on a strip of lifescan Inc., USA and the values were measured using the glucometer. Blood glucose is estimated at intervals of 48 and 72 hours after Streptozotocin administration, to the overnight fasted animals which was considered as zero blood glucose value. Animals with blood glucose levels 180 to 300 mg dl were selected for study. In ail, there were 3 groups one for amino acid composition, one for Phenformin and one for solvent control. The effect of the preparation of amino acids on blood glucose levels, was measured and evaluated in comparison to solvent and positive control groups. Amino acid composition and Phenformin were administered orally as suspension in 0.3% CMC twice a day for 6 days and blood glucose levels were measured on the 6th day. The statistical significance of the antihyperglycemic activity vis-a-vis solvent and positive control was evaluated using ANOVA. Results
The blood glucose levels after administration of amino acids were 45% lower than that of the control group and 29% lower than that of the Phenformin group (Positive control) indicating significant anti-diabetic activity for the amino acid composition.
It is to be understood that the dosage levels required for anti-diabetic activity are to be evaluated through pharmacokinetic studies and human trials. Since the composition of the present invention contains nutritional principles, safety is guaranteed and toxic effects are bound to be minimum.
The composition can be administered in a solid dosage form such as plain and coated tablets/hard gelatine capsules/soft gelatine capsules/powder in sachet/liquid dosage form like solution suspension and parental preparations.
Different dosage forms are prepared using the conventional excipients and the composition of the excipients may change depending upon the dosage form formulated.
Tablets or capsules are formulated by using suitable excipients like microcrystalline cellulose, potato starch, methyl cellulose, hydroxy propyl cellulose, dicalcium phosphate, poly ethylene glycol, hydroxy propyl methyl cellulose, talc, magnesium stearate etc. are used and the process for tabletting normally, not necessarily the same steps.
1. Dispensing 2. Sieving of raw material
3. Dry mixing
4. Wet granulation
5. Drying
6. Dry granulation
7. Blending
8. Compression
The capsules are formulated in two ways. They are
1. Direct filling of the amino acids with or without excipients in capsules.
2. Filling of extruded and spheronized granules into hard gelatine capsules. These granules are filled in 1/2/0/00 size capsules.
The same composition with or without the excipients can be used as a powder in a suitable packing like sachet etc..
This composition can be formulated into a liquid using pharmaceutical vehicles like sorbitol, water, sugar syrup, propylene glycol, glycerine in addition to flavours, buffers, antioxidants and preservatives.
EXAMPLE 1
The following non-limiting example shall serve to describe the invention.
The composition and process for extrusion and spheronisation technique is as follows.
Granules I mg cap
L-Lysine hydrochloride 250.00
L-Leucine 51.70
L-Cysteine hydrochloride 33.16
L-Glycine 20.55
Microcrystalline cellulose 45.00
Potato starch 5.99
Methyl cellulose 4.00
Hydroxy propyl cellulose 2.00
Tartrazine 0.60
P.E.G, 6000 2.00
Granules II mg cap
L-Glutamic acid 40.02
Microcrystalline cellulose 14.60
Potato starch 5.98
Methyl cellulose 2.00
Hydroxy propyl cellulose 2.00
Indigo carmine 0
The above ingredients are sieved through 40# and mixed in a suitable mixer for 30 mnts. And water is added slowly to obtain a soft mass. This is passed through an extruder and then spheronised. The spheronised granules are dried at 45 deg C for about 3 hours or till moisture content is less than
2.0% w/w. The above 2 granules are mixed in a suitable mixer for 1 hour. These granules are filled in 'O' size capsules.
The description given as above with respect to the material (excipients etc.) and process of the extrusion and spheronosation is an example. The same granules may be produced with different excipients and by modifying the process steps in the same technique.
These two granules can also be taken as single granules, by taking all the materials together.
EXAMPLE 2
The following non-limiting example shall serve to described the invention.
All the 5 amino acids namely, L-lysine hydrochloride, L-leucine, L- glycine, L-cysteine hydrochloride, L-glutamic acid were blended geometrically and the blended mix was used to test the hypoglycaemic effect in rats. Thirty six diabetic rats of either sex of Albino strain were used in the study. Animals were given streptozotocin (50mg/kg) to induce diabetes. To one group, the amino acid mix in 0.3% sodium carboxy methyl cellulose dispersion was administered twice a day, at a dose of 131.796 mg per dose for six days and blood glucose levels were checked at initial and at sixth day. However, the drug mix is administered for six days, twice a day. The other group was administered only 0.3% sodium carboxy methyl cellulose dispersion (solvent control group) at the same time intervals as that of the test group. The results are as follows :
Group Blood Glucose levels Initial 6th day
Control 260 510
Test 284 281
Positive control 275 398
(Phenformin)
As can be seen from the above data, the blood glucose levels of the test group were 45% lower than that of the control group and 29% lower than that of positive control group. The amino acid mixture could contain the raise in blood glucose level, in test group from the initial level, where as solvent treated control group continued to show significantly increasing blood glucose levels.

Claims

CLAIMS :
1. An anti-diabetic amino acid composition which comprises a combination essentially of L-Lysine, L-Leueine, L-Glutamic acid, L- Glycine and L-Cysteine and/or pharmaceutically acceptable salts thereof.
2. The composition as claimed in claim 1, a unit dose of which comprises of:
L- Lysine hydrochioride - 125.00 to 1000 mg L- Leucine - 25.85 to 206.80 mg
L- Cysteine hydrochloride - 16.58 to 132.64 mg L- Glycine - 10.275 to 82.20 mg
L- Glutamic acid - 20.01 to 160.08 mg, the balance being other amino acids and excipients.
3. The composition as claimed in claims 1 and 2, wherein L-Lysine is one part by weight, L-Leucine is 0.2068 part by weight, L-cysteine hydrochloride is 0.1326 part by weight, L-glycine is 0.0822 part by weight and L-glutamic acid is 0.1600 part by weight, the balance being diluents, excipients and other amino acids.
4. The composition as claimed in claim 1, which consists of 250 mg of L-Lysine hydrochloride, 51.7 mg of L-Leucine, 33.16 mg of L- cysteine hydrochloride, 20.55 mg of L-glycine and 40.02 mg of L-
5. glutamic acid in addition to excipients, colourants and other amino acids.
6. The composition as claimed in claims 1 to 4 in the form of powder, tablets, soft and hard gelatin capsules, suspensions, syrups, parenteral preparations.
7. The composition as claimed in claim 5, wherein the composition is in the form of pellets or spheronised granules.
8. Use of a composition essentially consisting of lysine, leucine, glycine, glutamic acid, and cysteine in treating Diabetes Mellitus.
9. Use of the composition as claimed in claim 7, either alone or in a mixture with known hypoglycemic agents and or insulin for treating diabetes.
AMENDED CLAIMS
[received by the International Bureau on 20 March 2002 (20.03.02); original claims 1-9 replaced by new claims 1-8 (2 pages)]
1. An anti-diabetic amino acid composition which comprises a combination of L-Lysine, L-Leucine, L-Glutamic acid, L-Glycine and L-Cysteine and/or pharmaceutically acceptable salts thereof.
2. The composition as claimed in claim 1, a unit dose of which comprises of:
L- Lysine hydrochloride - 125.00 to 1000 mg L- Leucine - 25.85 to 206.80 mg
L- Cysteine hydrochloride - 16.58 to 132.64 mg L- Glycine - 10.275 to 82.20 mg
L- Glutamic acid - 20.01 to 160.08 mg, the balance being excipients.
3. The composition as claimed in claims 1 and 2, wherein L-Lysine is one part by weight, L-Leucine is 0.2068 part by weight, L-Cysteine hydrochloride is 0.1326 part by weight, L-Glycine is 0.0822 part by weight and L-Glutamic acid is 0.1600 part by weight, the balance being diluents and excipients .
4. The composition as claimed in claim 1, which consists 250mg of L- Lysine hydrochloride, 51.7mg of L-Leucine, 33.16mg of L-Cysteine hydrochloride, 20.55mg of L-Glycine and40.02mg of L-Glutamic acid in addition to excipients and colourants.
5. The composition as claimed in claims 1 to 4 in the form of powder, tablets, hard gelatin and soft gelatin capsules, suspensions and syrups.
6. The composition as claimed in claim 5, wherein the composition is in the form of pellets or spheronised granules.
7. Use of a composition consisting of Lysine, Leucine, Glycine, Glutamic acid and Cysteine in treating diabetes mellitus.
8. Use of the composition a consisting of Lysine, Leucine, Glycine, Glutamic acid and Cysteine either alone or in a mixture with known hypoglycemic agents and/or insulin for treating diabetes.
PCT/IN2000/000128 2000-12-19 2000-12-19 An antidiabetic composition of amino acids WO2002049636A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001235976A AU2001235976A1 (en) 2000-12-19 2000-12-19 An antidiabetic composition of amino acids
PCT/IN2000/000128 WO2002049636A1 (en) 2000-12-19 2000-12-19 An antidiabetic composition of amino acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2000/000128 WO2002049636A1 (en) 2000-12-19 2000-12-19 An antidiabetic composition of amino acids

Publications (1)

Publication Number Publication Date
WO2002049636A1 true WO2002049636A1 (en) 2002-06-27

Family

ID=11076292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2000/000128 WO2002049636A1 (en) 2000-12-19 2000-12-19 An antidiabetic composition of amino acids

Country Status (2)

Country Link
AU (1) AU2001235976A1 (en)
WO (1) WO2002049636A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110394A1 (en) * 2004-05-19 2005-11-24 Ajinomoto Co., Inc. Therapeutic agent for diabetes
WO2006077202A1 (en) * 2005-01-18 2006-07-27 Dsm Ip Assets B.V. Novel nutraceutical compositions
WO2008120797A1 (en) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. Ampk activator
US20110237670A1 (en) * 2008-12-12 2011-09-29 Daniel Klamer Improvement of normal cognitive function
US20150011554A1 (en) * 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
WO2015052086A1 (en) * 2013-10-09 2015-04-16 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
EP3615936A4 (en) * 2017-04-25 2020-12-09 Almeda Labs LLC Amino acid formulations for pancreatic viability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279917A (en) * 1978-09-08 1981-07-21 Ajinomoto Company, Incorporated Amino acid solution for intravenous nutrition
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
JPS60255722A (en) * 1984-05-30 1985-12-17 Otsuka Pharmaceut Factory Inc Amino acid transfusion for diabetes
EP0917826A1 (en) * 1997-05-28 1999-05-26 Schwartz Riera, Simon Aminoacid formulations for third age persons and process for calculating such formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279917A (en) * 1978-09-08 1981-07-21 Ajinomoto Company, Incorporated Amino acid solution for intravenous nutrition
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
JPS60255722A (en) * 1984-05-30 1985-12-17 Otsuka Pharmaceut Factory Inc Amino acid transfusion for diabetes
EP0917826A1 (en) * 1997-05-28 1999-05-26 Schwartz Riera, Simon Aminoacid formulations for third age persons and process for calculating such formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198605, Derwent World Patents Index; AN 1986-033308, XP002954034 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110394A1 (en) * 2004-05-19 2005-11-24 Ajinomoto Co., Inc. Therapeutic agent for diabetes
JPWO2005110394A1 (en) * 2004-05-19 2008-03-21 味の素株式会社 Diabetes medicine
WO2006077202A1 (en) * 2005-01-18 2006-07-27 Dsm Ip Assets B.V. Novel nutraceutical compositions
EA012300B1 (en) * 2005-01-18 2009-08-28 ДСМ АйПи АССЕТС Б.В. Composition for treating or preventing diabetes mellitus and use thereof
WO2008120797A1 (en) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. Ampk activator
US20110237670A1 (en) * 2008-12-12 2011-09-29 Daniel Klamer Improvement of normal cognitive function
US20150011554A1 (en) * 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
JP2016521755A (en) * 2013-06-13 2016-07-25 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー Compositions and methods for treating metabolic disorders
WO2015052086A1 (en) * 2013-10-09 2015-04-16 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US9913818B2 (en) 2013-10-09 2018-03-13 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
AU2014333977B2 (en) * 2013-10-09 2019-12-19 Société des Produits Nestlé S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US11419838B2 (en) 2013-10-09 2022-08-23 Societe Des Produits Nestle S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US11957652B2 (en) 2013-10-09 2024-04-16 Societe Des Produits Nestle S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
EP3615936A4 (en) * 2017-04-25 2020-12-09 Almeda Labs LLC Amino acid formulations for pancreatic viability
US11224582B2 (en) 2017-04-25 2022-01-18 Almeda Labs Llc Amino acid formulations for pancreatic viability

Also Published As

Publication number Publication date
AU2001235976A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
US5922769A (en) Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II
EP2535044B1 (en) Enterically coated cysteamine bitartrate and cystamine
US20060269617A1 (en) Supplement compositions and method of use for enhancement of insulin sensitivity
EP1017408B1 (en) Use of tethrahydrolipstatin in the treatment of diabetes type ii
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
TW200918078A (en) Pharmaceutical composition comprising a pyrazole-O-glucoside derivative
WO2007119837A1 (en) Lipase inhibitor
US20140112983A1 (en) Nitrite compositions and uses thereof
AU2022204008A1 (en) Magnesium biotinate compositions and methods of use
WO2005049006A1 (en) Remedy for diabetes
WO2002049636A1 (en) An antidiabetic composition of amino acids
CN109689057A (en) For treating the composition and method of metabolism disorder
AU2014343262A1 (en) Herbal composition, process for its preparation and use thereof
JPH08337530A (en) Blood sugar depressant containing silkworm powder as effective component and its preparation
KR20080085358A (en) Composition comprising the extracts, fractions and the isolated compounds of thuja orientalis for prevention or treatment of diabetic complications
KR100824365B1 (en) Composition comprising the extracts, fractions and the isolated compounds of phyllostachys nigra munro for prevention or treatment of diabetic complications
WO2003015807A1 (en) Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives
KR20200107809A (en) Vitamin complex formula coated with xylitol and or Enzymatically Modified Stevia
KR20070086137A (en) Medicinal composition containing fbpase inhibitor
Dixitha et al. A review article of SGLT2 inhibitors for the treatment of diabetes and obesity
GB2500357A (en) Combination and composition for treating obesity
KR20020088498A (en) Pharmaceutical composition containing s-adenosylmethionine for decreasing insulin resistance
JP2003335665A (en) Composition for regulating in vivo vitamin c level
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
Chandramohan et al. REVIEW ON DEVELOPMENT OF SUSTAINED RELEASE CAPSULES INCORPORATING MATRIX GRANULES OF GLIMEPIRIDE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 600/CHENP/2003

Country of ref document: IN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP